TB Research

Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.

Nathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, Samanthi L Waidyarachchi, Jiuyu Liu, Joel N Rushefsky, Michelle M Butler, Terry Bowlin, et al. (14 authors)

Antimicrobial agents and chemotherapy · 2025-11

Abstract

Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events that limit its use. Here we present preclinical data comparing Nix-TB regimens anchored by either linezolid or spectinamide MBX-4888A.

MeSH terms

  • Animals
  • Linezolid
  • Antitubercular Agents
  • Mice
  • Mice, Inbred BALB C
  • Mycobacterium tuberculosis
  • Diarylquinolines
  • Spectinomycin
  • Female
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Nitroimidazoles
  • Microbial Sensitivity Tests
  • Adamantane
  • Ethylenediamines